Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors predominate as first-line therapy options for renal cell carcinoma. When first-line TKI therapy fails due to resistance development, an optimal second-line therapy has not yet been established. The present investigation is directed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Schnalke, Pascal, Rutz, Jochen, Maxeiner, Sebastian, Chun, Felix K.-H., Blaheta, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615644/
https://www.ncbi.nlm.nih.gov/pubmed/34829859
http://dx.doi.org/10.3390/biomedicines9111630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615644/
https://www.ncbi.nlm.nih.gov/pubmed/34829859
http://dx.doi.org/10.3390/biomedicines9111630

Ejemplares similares